Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study.
Gabriella FerrandinaGiacomo CorradoGiuseppe VitranoGallotta ValerioEleonora PalluzziMariagrazia DistefanoGiovanni ScambiaPublished in: Cancer chemotherapy and pharmacology (2018)
Dose-dense neo-adjuvant paclitaxel/carboplatin is feasible and safe in LACC patients; however, failure to achieve the primary end-point has to be recognized. Given the heterogeneity of the available studies, robust data from an adequately sized prospective study focused on more homogeneous series are required.
Keyphrases
- phase ii study
- locally advanced
- rectal cancer
- open label
- neoadjuvant chemotherapy
- squamous cell carcinoma
- end stage renal disease
- radiation therapy
- newly diagnosed
- minimally invasive
- chronic kidney disease
- early stage
- randomized controlled trial
- single cell
- placebo controlled
- electronic health record
- patient reported outcomes
- study protocol
- big data
- coronary artery disease
- acute coronary syndrome
- case control